Discovery Life Sciences’ Post

Discovery Life Sciences has a robust #biorepository of #biospecimens available from #autoimmunedisease patients available for immediate shipment to your facility. PBMCs, plasma, serum and FFPE are all available. Send me a DM if you need an inventory report! #PBMCs #FFPE #tissues #rheumatoidarthritis #SLE #lupus #psoriasis #autoimmune #researchanddevelopment #clinicalsamples

Join our webinar tomorrow at 4:00 PM to see how Ashvattha Therapeutics has discovered a way to deliver therapeutics to activated cells without impacting the healthy ones by using systemic treatments for inflammatory diseases. https://hubs.la/Q02sQXKm0

Join our webinar tomorrow at 4:00 PM to see how Ashvattha Therapeutics has discovered a way to deliver therapeutics to activated cells without impacting the healthy ones by using systemic treatments for inflammatory diseases. https://hubs.la/Q02sQN810

Join our webinar tomorrow at 4:00 PM to see how Ashvattha Therapeutics has discovered a way to deliver therapeutics to activated cells without impacting the healthy ones by using systemic treatments for inflammatory diseases. https://hubs.la/Q02sQSW40

Join our webinar on April 23rd at 4:00 PM to see how Ashvattha Therapeutics has discovered a way to deliver therapeutics to activated cells without impacting the healthy ones by using systemic treatments for inflammatory diseases. https://hubs.la/Q02sQXHz0

June is #AlzheimersandBrainAwarenessMonth, an important time to raise awareness of the significance of #brainhealth.  At Delix Therapeutics, we're developing first-in-class #neuroplastogens that promote the brain's innate ability to repair itself, and in doing so, pioneering a new era in #CNS disease treatment. Learn more about our science here: https://lnkd.in/eCRnJMv5.

Join our webinar on April 23rd at 4:00 PM to see how Ashvattha Therapeutics has discovered a way to deliver therapeutics to activated cells without impacting the healthy ones by using systemic treatments for inflammatory diseases. https://hubs.la/Q02sQSpr0

In this Did You Know article, we're looking into the world of bi- and multi-specific antibodies. The use of these engineered antibodies offers the potential for enhanced therapeutic strategies by simultaneously addressing multiple aspects of a disease. https://hubs.la/Q029gqxx0

Join our webinar tomorrow at 4:00 PM to see how Ashvattha Therapeutics has discovered a way to deliver therapeutics to activated cells without impacting the healthy ones by using systemic treatments for inflammatory diseases. https://hubs.la/Q02sQTyc0

Rheumatoid arthritis is one of the worst forms of #rheumatism. The results of our clinical trial, published in #TheLancet, show that early drug treatment can prevent the onset of rheumatoid arthritis for people whose blood test is positive for antibodies against citrulinated proteins (CCP). These findings are a great success for #InflammationResearchErlangen and were achieved by the Department of Medicine 3 - #Rheumatology and #Immunology at the #DeutschesZentrumImmunmedizin (DZI) at the Universitätsklinikum Erlangen of FAU Erlangen-Nürnberg leaded by Prof. Georg Schett and the team members consisting of Jürgen Rech, Koray Tascilar, Melanie Hagen, PD Dr. med Arnd Kleyer, Bernhard Manger, Verena Schönau, Axel Hueber, MD PhD, Stefan Kleinert, Xenofon Baraliakos, Jürgen Braun, Uta Kiltz, Martin Fleck, Andrea Rubbert, David M. Kofler, Frank Behrens MD, Martin Feuchtenberger, Michael Zaenker, Reinhard Voll, Nils Venhoff, Jens Thiel, Georg Schett https://lnkd.in/dekJCFHt #FAUMedFak, #rheumatoidarthritis, #clinicaltrial #DepartmentofMedicine3, #MedizinischeKlinik3, #immunology, #rheumatology